Independent of the underlying leukemia, hematological relapse after allo-SCT is associated with a poor prognosis. 1 Traditional approaches such as DLI and second transplant are often of limited value. Hence, early immune interventions, hypomethylating agents and targeted therapies such as tyrosine kinase inhibitors (TKI) [2] [3] [4] are currently used for the prevention or early treatment of post-transplant relapse.
Ponatinib is a highly effective drug for the treatment of advanced bcr/abl-positive leukemias. 5 However, detailed data on its use after allo-SCT are lacking. Here we present two cases, in which deep molecular response (MR4.5, according to standardized definitions of molecular response) 6 could be reinduced by ponatinib in patients with advanced relapse after allo-SCT and failure of other TKI.
Case 1: A 41-year-old female was diagnosed with Philadelphia chromosome-positive common ALL in September 2008. Matched unrelated allo-SCT was performed after achieving major molecular response (MMR), following myeloablative conditioning. Twenty-eight months after transplant, molecular relapse was detected and treated with imatinib for reinduction. After switching to dasatinib due to imatinib side effects, she achieved another MMR, which was consolidated by prophylactic DLI. Nevertheless, she developed hematological relapse with a complex aberrant karyotype and an isolated T315I mutation within the bcr/abl gene. The patient was refractory to salvage chemotherapy. After haploidentical second allo-SCT following myeloablative conditioning, given at 3 years after first transplant and 9 months after first molecular relapse, molecular undetectable disease (number of control gene copies: 368 800) was achieved. However, 6 months after the second allo-SCT, bcr/abl transcripts were detected again. None of the common bcr/abl mutations including T315i was detected. Ponatinib at a dosage of 45 mg/day was administered for remission induction. Rapid disease response was observed, with achievement of MR4.5 after o30 days of treatment. However, severe side effects including thrombocytopenia and skin alterations, mimicking cutaneous chronic GvHD occurred. Toxicities resolved rapidly after stopping ponatinib, but reappeared after it was restarted. Reduction of the ponatinib dose to 15 mg/day finally resulted in improvement of side effects to a mild and tolerable dryness of the skin, allowing for ongoing treatment. After 1 year with continuous MR4.5 we started prophylactic haploidentical DLI. Eight infusions could safely be given at a 4-5-week interval. An escalating dose schedule was used, starting with 0.61 × 10 5 up to 6.5 × 10 7 CD3+ cells per kg body wt. To avoid possible interactions between ponatinib and donor cells in the haploidentical setting, the drug was paused for 10 days after every DLI, but was continued thereafter. No changes in hematological parameters, and no signs of GvHD were observed. At last followup, the patient was in continuous MR4.5 at 30 months from haploidentical second allo-SCT while still on ponatinib 15 mg/day.
Case 2: A 58-year-old female with CML underwent allogeneic BM transplantation from her HLA-identical brother in the first chronic phase in 1986. Owing to the first hematological relapse, the patient received IFNα from February 1989 to January 1990, in combination with DLI in May 1989, resulting in CCyR. However, in January 2010, 25 years after diagnosis and 20 years after successful therapy of the first relapse post transplant, a second hematological relapse was diagnosed. For the first time she now received TKI. Application of nilotinib caused severe rash, imatinib was also poorly tolerated due to unspecific general symptoms. Nevertheless, MR4.5 was achieved with imatinib, and treatment was continued. After 2 years on imatinib, the bcr/abl ratio rose again. The dose escalation of imatinib to 800 mg was not tolerated due to severe muscular cramps, and similar side effects were seen with dasatinib. Six months later, the patient progressed to accelerated phase without detection of any mutation in the bcr/abl gene. Ponatinib (45 mg/day) was applied and led to MR2 within less than 1 month, and to MR4.5 within 3 months. Unfortunately, the patient developed a scleroderma-like skin reaction, again mimicking cGvHD (the latter being excluded by skin biopsy). Stopping ponatinib led to complete disappearance of the skin reaction within few days, but also to another molecular relapse, which was treated by DLI and restarting ponatinib at a dose of 15 mg/day. Also with this reduced dose, MR4.5 was re-established within 30 days. Unfortunately, severe cutaneous side effects reappeared, enforcing definitive discontinuation of ponatinib. The patient is now again receiving DLI and IFNα with a stable MR4.5 level.
The use of imatinib for the treatment of molecular and hematological relapse after allo-SCT has been widely established. Usually, treatment is efficacious and well tolerated in hematological CML relapse 2 and especially in patients with minimal residual disease.
3 Second-generation TKI also has shown promising results in this situation, either when given alone, or in combination with DLI. 4 Within the phase I and phase II studies on the thirdgeneration TKI ponatinib, forty-three patients have receivied ponatinib after allo-SCT, although efficacy and side effects of ponatinib in this particular setting were not analysed in detail. 5, 7 Therefore, we here present a detailed report on the efficacy and tolerability of ponatinib for the treatment of leukemia relapse following allo-SCT. In accordance with the most frequently observed side effects in non-transplant patients, thrombocytopenia, rash and dryness of the skin occurred early after initiation of ponatinib treatment, but were easily reversible upon discontinuation. 5 In both cases, ponatinib was given in very advanced stages of relapse, after failure of or poor tolerance of first and second-generation TKI, and relapse following DLI or second (hapoloidentical) allo-SCT. Nevertheless, kinetics of molecular response were rapid in both cases, showing achievement of MR4.5 within one and 3 months, respectively, after starting ponatinib. The antileukemic activity was maintained in both patients even after side effects had enforced the dose reduction to 15 mg/day. In non-transplant patients, the toxicity of ponatinib could be clearly correlated with higher doses, whereas the correlation between dose and clinical efficacy is still a matter of debate. 8 In a most recent publication at the meeting of the American Society of Clinical Oncology 2014, response rates were associated with dose intensity to a certain extent, whereas maintenance of response after dose reduction was seen in 490% of patients. 9 Our clinical observation in patients receiving ponatinib for advanced relapse after allo-SCT resembled the findings in non-transplant patients, both with respect to high antileukemic efficacy and side effects. Further data are required to definitively establish the role, toxicity and dosage of ponatinib in the post-transplant setting, as well as its use in the context of DLI.
